Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;3(18):261.
doi: 10.3978/j.issn.2305-5839.2015.10.18.

The relevance of molecular biomarkers in cervical cancer patients treated with radiotherapy

Sarah Kilic  1 , Bernadette Cracchiolo  1 , Molly Gabel  1 , Bruce Haffty  1 , Omar Mahmoud  1
Affiliations

The relevance of molecular biomarkers in cervical cancer patients treated with radiotherapy

Sarah Kilic et al. Ann Transl Med. 2015 Oct.

Abstract

Background: Radiotherapy (RT) plays an integral role in the combined-modality management of cervical cancer. Various molecular mechanisms have been implicated in the adaptive cellular response to RT. Identification of these molecular processes may permit the prediction of treatment outcome and enhanced radiation-induced cancer cell killing through tailoring of the management approach, and/or the employment of selective inhibitors of these pathways.

Methods: PubMed was searched for studies presenting biomarkers of cervical cancer radioresistance validated in patient studies or in laboratory experimentation.

Results: Several biomarkers of cervical cancer radioresistance are validated by patient survival or recurrence data. These biomarkers fall into categories of biological function including hypoxia, cell proliferation, cell-cell adhesion, and evasion of apoptosis. Additional radioresistance biomarkers have been identified in exploratory experiments.

Conclusions: Biomarkers of radioresistance in cervical cancer may allow molecular profiling of individual tumors, leading to tailored therapies and better prognostication and prediction of outcomes.

Keywords: Cervical cancer; biomarker; radiation therapy; radioresistance.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Visualization of the major biomarkers of radioresistance in cervical cancer, their biological functions, and their interrelationships.
Figure 2
Figure 2
Hazard ratio and 95% confidence interval for association of biomarkers with radioresistance. For studies that provided hazard ratios for multiple outcomes, outcome is indicated in parentheses after biomarker.
See this image and copyright information in PMC

References

    1. Benedet JL, Bender H, Jones H, 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62. - PubMed
    1. Peralta-Zaragoza O, Bermúdez-Morales VH, Pérez-Plasencia C, et al. Targeted treatments for cervical cancer: a review. Onco Targets Ther 2012;5:315-28. - PMC - PubMed
    1. Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus and cervical cancer. Lancet 2013;382:889-99. - PubMed
    1. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005;(3):CD002225. - PMC - PubMed
    1. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-25. - PubMed